[New tumor suppressor genes intervening in the regulation of the cycle]

¹INSERM U409, Faculté Xavier Bichat, Paris, France.

|January 1, 1994

Abstract:

Eukaryotic cell cycle progression is governed by multiple cyclin and cyclin-dependent kinases interactions that are in turn regulated by multiple factors. Recently, inhibitors of cyclin/cyclin-dependent kinases activities have been characterized and their genes have been cloned. Alterations of some these genes may play a major in tumor initiation or progression.

Insights

Cell cycle progression relies on cyclin and cyclin-dependent kinases. Inhibitors targeting these interactions are key for understanding and potentially treating cancer progression.

Area of Science:

Molecular Biology
Cell Biology
Genetics

Context:

Eukaryotic cell cycle control involves complex interactions between cyclins and cyclin-dependent kinases.
These interactions are regulated by numerous cellular factors.
Recent advancements include the characterization of inhibitors targeting cyclin/cyclin-dependent kinase activities and the cloning of their respective genes.

Purpose:

To review the regulatory mechanisms of eukaryotic cell cycle progression.
To highlight the significance of cyclin and cyclin-dependent kinase inhibitors.
To discuss the potential role of alterations in these genes in tumorigenesis.

Summary:

Eukaryotic cell cycle progression is orchestrated by intricate networks of cyclin and cyclin-dependent kinase (CDK) interactions.
These critical regulators are subject to modulation by various cellular factors.
The identification and cloning of genes encoding inhibitors of cyclin/CDK activity represent a significant recent development.

Impact:

Understanding these molecular pathways is crucial for cancer research.
Alterations in genes associated with cyclin/CDK regulation may contribute to tumor initiation and progression.
This knowledge could pave the way for novel therapeutic strategies targeting cell cycle dysregulation in cancer.

Read full analysis

Related Experiment Videos

[New tumor suppressor genes intervening in the regulation of the cycle]

Insights

Related Concept Videos

Unexpected extradermatological findings in 31 patients with xeroderma pigmentosum type C.

Intragenic rearrangements in LARGE and POMGNT1 genes in severe dystroglycanopathies.

EDNRB gene variants and melanoma risk in two southern European populations.

[Intra- and interfamilial phenotype variation in Birt-Hogg-Dubé syndrome: Consequences for therapy].

Xeroderma pigmentosum group C in a French Caucasian patient with multiple melanoma and unusual long-term survival.

PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study.

Intranuclear arrangement of human chromosome 12 is reflected in metaphase chromosomes as non-random bending.

Trisomy 4 associated with double minute chromosomes and MYC amplification in acute myeloblastic leukemia.

Large duplication 4q25-q34 with mild clinical effect.

A submicroscopic unbalanced subtelomeric translocation t(2p;10q) identified by fluorescence in situ hybridization: fetus with increased nuchal translucency and normal standard karyotype with later growth and developmental delay, rhombencephalosynapsis (RES).

Partial trisomy 8q and partial monosomy 18p: a case report.

Partial trisomy 18q11.2-->qter due to de novo unbalanced translocation of chromosomes 15 and 18 analyzed by fluorescence in situ hybridization.

Targeting Cancer-Associated Fibroblasts with Small-Molecule Inhibitors: Molecular Mechanisms and Therapeutic Potential.

A novel multiplex digital PCR assay for simultaneous quantification of androgen receptor amplification, mutations, and splice variants in cell-free nucleic acids from metastatic castration-resistant prostate cancer.

EGFR-antibody-decorated cancer-cell-membrane-coated MOF nanoplatform enables targeted delivery of the STING agonist diABZI for pancreatic cancer immunotherapy.

Targeting Muscle-Specific E3 Ligases in Cancer Cachexia Through Structure-Based Virtual Screening of Small-Molecule Inhibitors.

Targeting MAT2A-S-adenosylmethionine (SAM) Axis Attenuates DNA Damage Response and Cancer Stemness to Increase Platinum Sensitivity in Ovarian Cancer.

Modulation of the FAK-Src Signalling Axis by Oncoviruses: Molecular Mechanisms, Functional Consequences, and Therapeutic Opportunities.

Related Experiment Videos

[New tumor suppressor genes intervening in the regulation of the cycle]

Abstract:

Insights

Related Concept Videos

Related Articles